866-997-4948(US-Canada Toll Free)

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Published By :

GBI Research

Published Date : Apr 2011

Category :

Cancer

No. of Pages : 137 Pages


GBI Research, the leading business intelligence provider, has released its latest research, Cancer Supportive Care Products Market to 2016 Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars, which provides insights into the cancer supportive care products market and forecasts until 2016. 

The report provides an in-depth analysis of the six major cancer supportive care products indications, which are oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases. The report also looks into the major unmet needs in the cancer supportive care products market and the major classes of drugs that treat the indications covered in the sector. 

The report also analyzes the key drivers and restraints that are expected to impact each of the indications in the global cancer supportive care products market. The report also delves into the cancer supportive care products market in the top seven countries in the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. In addition, the report also includes insights into the R&D (Research & Development) pipeline for the six cancer supportive care indications. In addition, the report also looks into the major M&A (Mergers & Acquisitions) and licensing deals that have taken place between 2008 and 2010 in the global cancer supportive care products market space. 

Scope

The scope of this report includes - 
  • Data and analysis on the cancer supportive care products market.
  • Annualized market data for the cancer supportive care products market from 2001 to 2009, with forecasts to 2016.
  • Market data on the therapeutic landscape which covers oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases, including market size, market share, annual cost of therapy, treatment usage patterns such as prevalence population and prescription population.
  • Key drivers and restraints that have had a significant impact on the market and on each indication.
  • The geographic landscape that covers the US, the top five countries of Europe (the UK, France, Germany, Spain and Italy) and Japan.
  • The competitive landscape of the cancer supportive care products market which includes companies such as Amgen, Johnson & Johnson, Roche, Novartis and Pfizer
  • Key M&A activities and Licensing Agreements that took place from 2008 to 2010 in the cancer supportive care products market.
Reasons to buy

The report will enhance your decision making capability. It will allow you to - 

  • Align your product portfolio to the markets with high growth potential.
  • Develop market-entry and market expansion strategies by identifying the leading countries and therapeutic segments poised for strong growth.
  • Devise a more tailored country strategy through the understanding of key drivers and barriers of each regions pharmaceutical market.
  • Develop key strategic initiatives by understanding the key focus areas of leading companies.
  • Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.
Table of Contents

1 Table of Contents

1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 9

2 Cancer Supportive Care Products Market: Introduction 12
2.1 GBI Research Report Guidance 12

3 Cancer Supportive Care Products Market: Market Overview 13
3.1 Revenue 13
3.2 Average Annual Cost of Therapy 14
3.3 Therapeutic Segmentation 15
3.4 Geographic Segmentation 16
3.5 Generic Share in the Cancer Supportive Care Products Market 20
3.6 Drivers and Restraints of Cancer Supportive Care Products Market 21
3.6.1 Drivers 21
3.6.2 Restraints 22
3.7 Unmet Needs 23
3.7.1 Efficacy 23
3.7.2 Safety 23
3.7.3 Price 23
3.8 Major Drug Classes 24
3.8.1 Anti-infectives (Oral Mucositis) 24
3.8.2 Anti-emetics (CINV) 24
3.8.3 Bisphosphonates (Bone Metastases) 25
3.8.4 Erythropoietin Stimulating Agents (CIA) 25
3.8.5 Granulocyte Colony Stimulating Factors (CINP) 26
3.8.6 Opioid Analgesics (Cancer Pain and Bone Metastases) 26
3.8.7 NSAIDs (Cancer Pain and Bone Metastases) 26
3.8.8 Monoclonal Antibodies (Bone Metastases) 27

4 Cancer Supportive Care Products Market: Therapeutic Landscape 28
4.1 Oral Mucositis and Dry Mouth Market 28
4.1.1 Introduction 28
4.1.2 Revenue 29
4.1.3 Annual Cost of Therapy 30
4.1.4 Treatment Usage Patterns 31
4.1.5 Drivers for the Oral Mucositis and Dry Mouth Market 33
4.1.6 Restraints for the Oral Mucositis and Dry Mouth Market 34
4.1.7 Geographical Segmentation 34
4.2 Chemotherapy Induced Nausea and Vomiting Market 38
4.2.1 Introduction 38
4.2.2 Revenue 40
4.2.3 Annual Cost of Therapy 41
4.2.4 Treatment Usage Patterns 42
4.2.5 Drivers for the Chemotherapy Induced Nausea and Vomiting Market 44
4.2.6 Restraints for the Chemotherapy Induced Nausea and Vomiting Market 45
4.2.7 Geographical Landscape 46
4.3 Cancer Pain Market 49
4.3.1 Introduction 49
4.3.2 Revenue 49
4.3.3 Annual Cost of Therapy 50
4.3.4 Treatment Usage Patterns 51
4.3.5 Drivers for the Cancer Pain Market 56
4.3.6 Restraints for the Cancer Pain Market 56
4.3.7 Geographical Landscape 57
4.4 Chemotherapy Induced Anemia Market 60
4.4.1 Introduction 60
4.4.2 Revenue 60
4.4.3 Annual Cost of Therapy 62
4.4.4 Treatment Usage Patterns 63
4.4.5 Drivers for the Chemotherapy Induced Anemia Market 66
4.4.6 Restraints for the Chemotherapy Induced Anemia Market 66
4.4.7 Geographical Landscape 67
4.5 Chemotherapy Induced Neutropenia Market 70
4.5.1 Introduction 70
4.5.2 Revenue 71
4.5.3 Annual Cost of Therapy 72
4.5.4 Treatment Usage Patterns 73
4.5.5 Drivers for the Chemotherapy Induced Neutropenia Market 76
4.5.6 Restraints for the Chemotherapy Induced Neutropenia Market 76
4.5.7 Geographical Landscape 77
4.6 Bone Metastases Market 79
4.6.1 Introduction 79
4.6.2 Revenue 80
4.6.3 Annual Cost of Therapy 81
4.6.4 Treatment Usage Patterns 82
4.6.5 Drivers for the Bone Metastases Market 85
4.6.6 Restraints for the Bone Metastases Market 85
4.6.7 Geographical Landscape 86

5 Cancer Supportive Care Products Market: Geographical Landscape 89
5.1 The US 89
5.1.1 Revenue 89
5.1.2 Average Annual Cost of Therapy 90
5.1.3 Therapeutic Segmentation 91
5.2 Top Five Countries of Europe 92
5.2.1 Revenue 92
5.2.2 Average Annual Cost of Therapy 93
5.2.3 Therapeutic Segmentation 94
5.2.4 Geographic Segmentation 95
5.3 Japan 96
5.3.1 Revenue 96
5.3.2 Average Annual Cost of Therapy 97
5.3.3 Therapeutic Segmentation 98

6 Cancer Supportive Care Products Market: Pipeline Analysis 99
6.1 Introduction 99
6.1.1 Research and Development Pipeline Oral Mucositis and Dry Mouth 101
6.1.2 Research and Development Pipeline Chemotherapy Induced Nausea and Vomiting 102
6.1.3 Research and Development Pipeline Cancer Pain 103
6.1.4 Research and Development Pipeline Chemotherapy Induced Anemia 104
6.1.5 Research and Development Pipeline Chemotherapy Induced Neutropenia 105
6.1.6 Research and Development Pipeline Bone Metastases 106
6.2 Profiles of Promising Drugs in the Cancer Supportive Care Products Market 107
6.2.1 Xgeva/Prolia (denosumab) Bone Metastases 107
6.2.2 Alpharadin Bone Metastases 108
6.2.3 MAXY-G34 Chemotherapy Induced Neutropenia 109
6.2.4 Lactermin Oral Mucositis 109
6.2.5 Xen2174 Cancer Pain 110
6.2.6 Tectin Cancer Pain 111
6.2.7 NasalFent Cancer Pain 112

7 Cancer Supportive Care Products Market: Competitive Landscape 113
7.1 Market Share Analysis 113
7.2 Competitive Profiling 114
7.2.1 Amgen 114
7.2.2 Johnson & Johnson 116
7.2.3 F. Hoffmann-La Roche 118
7.2.4 Novartis 120
7.2.5 Pfizer 122

8 Cancer Supportive Care Products Market: Deals Landscape 124
8.1 M&A and Licensing Agreements 124
8.1.1 Deals by Year 124
8.1.2 Deals by Deal Type 125
8.1.3 Deals by Indication 126
8.1.4 Deals by Value ($m) 127
8.1.5 Deals by Geography 128
8.1.6 Major Acquisitions in the Cancer Supportive Care Products Market 128
8.1.7 Major Licensing Agreements in the Cancer Supportive Care Products Market 129

9 Cancer Supportive Care Products Market: Appendix 131
9.1 Market Definitions 131
9.2 Abbreviations 131
9.3 Research Methodology 133
9.3.1 Coverage 133
9.3.2 Primary Research 134
9.3.3 Forecasts 134
9.3.4 Expert Panel Validation 136
9.4 Contact Us 137
9.5 Disclaimer 137
9.6 Sources 137

List of Table


Table 1: Cancer Supportive Care Products Market, Global, Revenue ($m), 20012009 13
Table 2: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 20092016 13
Table 3: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 20012009 14
Table 4: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 20092016 14
Table 5: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 20012009 16
Table 6: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 20092016 17
Table 7: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2009 20
Table 8: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2009-2016 20
Table 9: Oral Mucositis and Dry Mouth, Global, Revenue ($m), 20012009 29
Table 10: Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 20092016 29
Table 11: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 20012009 30
Table 12: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 20092016 30
Table 13: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (000), 20012009 31
Table 14: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (000), 20092016 31
Table 15: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 20012009 35
Table 16: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 20092016 35
Table 17: Chemotherapy Induced Nausea and Vomiting, Emetic Risk Levels of Major Chemotherapeutic Agents 39
Table 18: Chemotherapy Induced Nausea and Vomiting, Global, Revenue ($m), 20012009 40
Table 19: Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 20092016 40
Table 20: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 20012009 41
Table 21: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 20092016 41
Table 22: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (000), 20012009 42
Table 23: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (000), 20092016 42
Table 24: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 20012009 46
Table 25: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 20092016 46
Table 26: Cancer Pain, Global, Revenue ($m), 20012009 49
Table 27: Cancer Pain, Global, Revenue Forecast ($m), 20092016 50
Table 28: Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2009 50
Table 29: Cancer Pain, Global, Annual Cost of Therapy ($), 2009-2016 50
Table 30: Cancer Pain, Global, Treatment Usage Patterns (000), 2001-2009 51
Table 31: Cancer Pain, Global, Treatment Usage Patterns (000), 2009-2016 52
Table 32: Cancer Pain, Geographical Segmentation, Revenue ($m), 20012009 57
Table 33: Cancer Pain, Geographical Segmentation, Revenue ($m), 20092016 57
Table 34: Chemotherapy Induced Anemia, Global, Revenue ($m), 20012009 61
Table 35: Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 20092016 61
Table 36: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 20012009 62
Table 37: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 20092016 62
Table 38: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (000), 20012009 63
Table 39: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (000), 20092016 63
Table 40: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 20012009 67
Table 41: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 20092016 67
Table 42: Chemotherapy Induced Neutropenia, Global, Revenue ($m), 20012009 71
Table 43: Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 20092016 71
Table 44: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 20012009 72
Table 45: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 20092016 72
Table 46: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (000), 20012009 73
Table 47: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (000), 20092016 73
Table 48: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 20012009 77
Table 49: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 20092016 77
Table 50: Bone Metastases, Global, Revenue ($m), 20012009 80
Table 51: Bone Metastases, Global, Revenue Forecast ($m), 20092016 80
Table 52: Bone Metastases, Global, Annual Cost of Therapy ($), 20012009 81
Table 53: Bone Metastases, Global, Annual Cost of Therapy ($), 20092016 81
Table 54: Bone Metastases, Global, Treatment Usage Pattern (000), 20012009 82
Table 55: Bone Metastases, Global, Treatment Usage Pattern (000), 20092016 82
Table 56: Bone Metastases, Geographical Segmentation, Revenue ($m), 20012009 86
Table 57: Bone Metastases, Geographical Segmentation, Revenue ($m), 20092016 86
Table 58: Cancer Supportive Care Products Market, the US, Revenue ($m), 20012009 89
Table 59: Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 20092016 89
Table 60: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 20012009 90
Table 61: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 20092016 90
Table 62: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue ($m), 20012009 92
Table 63: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 20092016 92
Table 64: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 20012009 93
Table 65: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 20092016 94
Table 66: Cancer Supportive Care Products Market, Japan, Revenue ($m), 20012009 96
Table 67: Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 20092016 96
Table 68: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 20012009 97
Table 69: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 20092016 97
Table 70: Cancer Supportive Care Products Market, Global, Pipeline Products Amgen, 2011 115
Table 71: Cancer Supportive Care Products Market, Global, Pipeline Products Johnson & Johnson, 2011 117
Table 72: Cancer Supportive Care Products Market, Global, Pipeline Products F. Hoffmann-La Roche, 2011 119
Table 73: Cancer Supportive Care Products Market, Global, Pipeline Products Novartis, 2011 121
Table 74: Cancer Supportive Care Products Market, Global, Pipeline Products Pfizer, 2011 123

List of Chart


Figure 1: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 20012016 13
Figure 2: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 20012016 14
Figure 3: Cancer Supportive Care Products Market, Global, Market Share by Indication (%), 2009 and 2016 15
Figure 4: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 20012016 16
Figure 5: Cancer Supportive Care Products Market, Market Share by Geography (%), 2009 and 2016 18
Figure 6: Cancer Supportive Care Products Market, Market Share of the Top Five Countries of Europe (%), 2009 and 2016 19
Figure 7: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2016 20
Figure 8: Oral Mucositis and Dry Mouth, World Health Organization Toxicity-based Classification for Oral Mucositis, 2011 28
Figure 9: Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 20012016 29
Figure 10: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 20012016 30
Figure 11: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern (000), 20012016 31
Figure 12: Oral Mucositis and Dry Mouth, Global, Prevalence Population (000), 20012016 32
Figure 13: Oral Mucositis and Dry Mouth, Global, Prescription Population (000), 20012016 33
Figure 14: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 20012016 34
Figure 15: Oral Mucositis and Dry Mouth, Market Share by Geography (%), 2009 and 2016 36
Figure 16: Oral Mucositis and Dry Mouth, Market Share of Top Five Countries of Europe (%), 2009 and 2016 37
Figure 17: Chemotherapy Induced Nausea and Vomiting, Classification and Risk Factors, 2011 38
Figure 18: Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 20012016 40
Figure 19: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 20012016 41
Figure 20: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern (000), 20012016 42
Figure 21: Chemotherapy Induced Nausea and Vomiting, Global, Prevalence Population (000), 20012016 43
Figure 22: Chemotherapy Induced Nausea and Vomiting, Global, Prescription Population (000), 20012016 44
Figure 23: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 20012016 46
Figure 24: Chemotherapy Induced Nausea and Vomiting, Market Share by Geography (%), 2009 and 2016 47
Figure 25: Chemotherapy Induced Nausea and Vomiting, Market Share of Top Five Countries of Europe (%), 2009 and 2016 48
Figure 26: Cancer Pain, Global, Revenue Forecast ($m), 20012016 49
Figure 27: Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2016 50
Figure 28: Cancer Pain, Global, Treatment Usage Patterns (000), 2001-2016 51
Figure 29: Cancer Pain, Global, Prevalence Population (000), 2001-2016 52
Figure 30: Cancer Pain, Global, Treatment Seeking Population (000), 2001-2016 53
Figure 31: Cancer Pain, Global, Diagnosed Population (000), 2001-2016 54
Figure 32: Cancer Pain, Global, Prescription Population (000), 2001-2016 55
Figure 33: Cancer Pain, Geographical Segmentation, Revenue ($m), 20012016 57
Figure 34: Cancer Pain, Market Share by Geography (%), 2009 and 2016 58
Figure 35: Cancer Pain, Market Share of Top Five Countries of Europe (%), 2009 and 2016 59
Figure 36: Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 20012016 60
Figure 37: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 20012016 62
Figure 38: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern (000), 20012016 63
Figure 39: Chemotherapy Induced Anemia, Global, Prevalence Population (000), 20012016 64
Figure 40: Chemotherapy Induced Anemia, Global, Prescription Population (000), 20012016 65
Figure 41: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 20012016 67
Figure 42: Chemotherapy Induced Anemia, Market Share by Geography (%), 2009 and 2016 68
Figure 43: Chemotherapy Induced Anemia, Market Share of Top Five Countries of Europe (%), 2009 and 2016 69
Figure 44: Chemotherapy Induced Neutropenia, National Cancer Institutes Common Toxicity Criteria for CINP, 2011 70
Figure 45: Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 20012016 71
Figure 46: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 20012016 72
Figure 47: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern (000), 20012016 73
Figure 48: Chemotherapy Induced Neutropenia, Global, Prevalence Population (000), 20012016 74
Figure 49: Chemotherapy Induced Neutropenia, Global, Prescription Population (000), 20012016 75
Figure 50: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 20012016 77
Figure 51: Chemotherapy Induced Neutropenia, Market Share by Geography (%), 2009 and 2016 78
Figure 52: Chemotherapy Induced Neutropenia, Market Share of Top Five Countries of Europe (%), 2009 and 2016 79
Figure 53: Bone Metastases, Global, Revenue Forecast ($m), 20012016 80
Figure 54: Bone Metastases, Global, Annual Cost of Therapy ($), 20012016 81
Figure 55: Bone Metastases, Global, Treatment Usage Pattern (000), 20012016 82
Figure 56: Bone Metastases, Global, Prevalence Population (000), 20012016 83
Figure 57: Bone Metastases, Global, Prescription Population (000), 20012016 84
Figure 58: Bone Metastases, Geographical Segmentation, Revenue ($m), 20012016 86
Figure 59: Bone Metastases, Market Share by Geography (%), 2009 and 2016 87
Figure 60: Bone Metastases, Market Share of Top Five Countries of Europe (%), 2009 and 2016 88
Figure 61: Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 20012016 89
Figure 62: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 20012016 90
Figure 63: Cancer Supportive Care Products Market, the US, Market Share by Indication (%), 2009 and 2016 91
Figure 64: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 20012016 92
Figure 65: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 20012016 93
Figure 66: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Indication (%), 2009 and 2016 94
Figure 67: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Country (%), 2009 and 2016 95
Figure 68: Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 20012016 96
Figure 69: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 20012016 97
Figure 70: Cancer Supportive Care Products Market, Japan, Market Share by Indication (%), 2009 and 2016 98
Figure 71: Cancer Supportive Care Products, Global, Pipeline by Indication, 2010 99
Figure 72: Cancer Supportive Care Products, Global, Pipeline by Phase (%), 2010 100
Figure 73: Oral Mucositis and Dry Mouth, Global, Pipeline by Phase (%), 2010 101
Figure 74: Chemotherapy Induced Nausea and Vomiting, Global, Pipeline by Phase (%), 2010 102
Figure 75: Cancer Pain, Global, Pipeline by Phase (%), 2010 103
Figure 76: Chemotherapy Induced Anemia, Global, Pipeline by Phase (%), 2010 104
Figure 77: Chemotherapy Induced Neutropenia, Global, Pipeline by Phase (%), 2010 105
Figure 78: Bone Metastases, Global, Pipeline by Phase (%), 2010 106
Figure 79: Cancer Supportive Care Products Market, Global, Market Share by Companies (%), 2009 113
Figure 80: Cancer Supportive Care Products Market, Amgen SWOT Analysis, 2011 116
Figure 81: Cancer Supportive Care Products Market, Johnson & Johnson SWOT Analysis, 2011 118
Figure 82: Cancer Supportive Care Products Market, F. Hoffmann-La Roche SWOT Analysis, 2011 119
Figure 83: Cancer Supportive Care Products Market, Novartis SWOT Analysis, 2011 121
Figure 84: Cancer Supportive Care Products Market, Pfizer SWOT Analysis, 2011 123
Figure 85: Cancer Supportive Care Products Market, Global, M&A and Licensing Agreements by Year, 20082010 124
Figure 86: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Type, 20082010 125
Figure 87: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Indication, 20082010 126
Figure 88: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Value, 20082010 127
Figure 89: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Geography, 20082010 128
Figure 90: GBI Research Market Forecasting Model 136

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *